Latest Deals

This acquisition is part of Merck’s plans to restructure its portfolio. Credit: Merck & Co., Inc.

Merck has agreed to acquire biopharmaceutical company Verona Pharma in a deal valued at $10bn. The acquisition will be made by the subsidiary of Merck, which is known as MSD outside of the US and Canada. The transaction will enhance Merck’s cardio-pulmonary pipeline and portfolio with the addition of Ohtuvayre (ensifentrine), an FDA-approved treatment for chronic obstructive pulmonary disease (COPD) in adults.

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary closing conditions. The merger, announced in April 2025, will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027.

Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year. Sino already owns a 4.91% stake courtesy of an investment in November 2024, with the company now seeking to purchase the remaining 95.09% it does not own.

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in a $2bn deal. The transaction includes an upfront payment of $1.2bn and potential milestone payments of $800m. The acquisition, announced in May 2025, saw GSK purchase Boston Pharmaceuticals’ subsidiary BP Asset IX.